{"id":24133,"date":"2023-08-23T11:36:56","date_gmt":"2023-08-23T09:36:56","guid":{"rendered":"https:\/\/idibell.cat\/?p=24133"},"modified":"2023-08-23T11:36:56","modified_gmt":"2023-08-23T09:36:56","slug":"un-biomarcador-dimatge-pot-ajudar-a-comprendre-i-tractar-millor-lesclerosi-multiple-progressiva","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2023\/08\/un-biomarcador-dimatge-pot-ajudar-a-comprendre-i-tractar-millor-lesclerosi-multiple-progressiva\/","title":{"rendered":"Un biomarcador d\u2019imatge pot ajudar a comprendre i tractar millor l\u2019esclerosi m\u00faltiple progressiva"},"content":{"rendered":"

Un treball de recerca liderat per neuroradi\u00f2legs i neur\u00f2legs de l\u2019IDIBELL, l\u2019Hospital Universitari de Bellvitge i l\u2019Institut de Diagn\u00f2stic per la Imatge ha identificat un nou biomarcador de resson\u00e0ncia magn\u00e8tica. Aquest biomarcador permetria detectar amb precisi\u00f3 focus d\u2019inflamaci\u00f3 cerebral cr\u00f2nica, associats a la forma progressiva de l\u2019esclerosi m\u00faltiple.<\/p>\n

La investigaci\u00f3, publicada aquest mes de juny a la prestigiosa revista European Radiology<\/em><\/a>, \u00e9s el primer fruit d\u2019una nova l\u00ednia de col\u00b7laboraci\u00f3 entre el Servei de Radiodiagn\u00f2stic i la Unitat d\u2019Esclerosi M\u00faltiple \u2013 EMXarxa de l\u2019Hospital Universitari de Bellvitge. Aquesta col\u00b7laboraci\u00f3 t\u00e9 com a objectiu fer recerca a nivell d\u2019imatge en esclerosi m\u00faltiple.<\/p>\n

En aquest estudi, liderat pel neuroradi\u00f2leg i investigador de l\u2019IDIBELL Pablo Naval Baud\u00edn, s\u2019analitzen\u00a0 les caracter\u00edstiques de les lesions de subst\u00e0ncia blanca cerebral anomenades phase rim lesions<\/em> (lesions de ribet de paramagn\u00e8tic). Aquestes lesions es consideren potencials biomarcadors de la forma progressiva de la malaltia, per\u00f2 la seva detecci\u00f3 \u00e9s complexa i requereix de t\u00e8cniques avan\u00e7ades de imatge que no sempre estan disponibles i que s\u00f3n dif\u00edcils de quantificar de manera objectiva.<\/p>\n

Gr\u00e0cies a les dades cl\u00edniques aportades pels neur\u00f2legs i l\u2019an\u00e0lisi feta pels radi\u00f2legs de les exploracions a pacients amb aquesta lesi\u00f3 i a pacients amb altres lesions, s\u2019ha determinat que l\u2019\u00fas d\u2019imatges ponderades en T1 tridimensional \u2013un tipus d\u2019imatge de resson\u00e0ncia magn\u00e8tica est\u00e0ndard i \u00e0mpliament accessible\u2013 permet detectar les phase-rim lesions<\/em> i quantificar-les d\u2019una manera relativament senzilla i objectiva.<\/p>\n

Aquesta descoberta obre la porta a estudiar el seu \u00fas com a biomarcadors d\u2019\u00fas senzill per detectar preco\u00e7ment la forma progressiva de la malaltia i per millorar-ne els tractaments.<\/p>\n

Els pacients que pateixen la forma progressiva de l\u2019esclerosi m\u00faltiple no aconsegueixen el control i la remissi\u00f3 dels brots i van desenvolupant una discapacitat greu al llarg dels anys. Fins fa poc no hi havia ter\u00e0pies efectives per a ells, per\u00f2 recentment han aparegut tractaments que fan que treballs de recerca com aquest tinguin una gran import\u00e0ncia.<\/p>\n

Els resultats apuntats per l\u2019estudi i la seva aplicaci\u00f3 cl\u00ednica s\u2019hauran de confirmar i desenvolupar amb posteriors investigacions.<\/p>\n

 <\/p>\n

 <\/p>\n

L\u2019Institut d’Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u00e9s un centre de recerca en biomedicina creat l\u2019any 2004. Est\u00e0 participat per l’Hospital Universitari de Bellvitge i l\u2019Hospital de Viladecans de l’Institut Catal\u00e0 de la Salut, l’Institut Catal\u00e0 d’Oncologia, la Universitat de Barcelona i l\u2019Ajuntament de l\u2019Hospitalet de Llobregat.<\/em><\/p>\n

L\u2019IDIBELL \u00e9s membre del Campus d’Excel\u00b7l\u00e8ncia Internacional de la Universitat de Barcelona HUBc i forma part de la instituci\u00f3 CERCA de la Generalitat de Catalunya. L’any 2009 es va convertir en un dels cinc primers centres d\u2019investigaci\u00f3 espanyols acreditats com a institut d\u2019investigaci\u00f3 sanit\u00e0ria per l\u2019Instituto de Salud Carlos III. A m\u00e9s, forma part del programa \u201cHR Excellence in Research\u201d de la Uni\u00f3 Europea i \u00e9s membre de EATRIS i REGIC. Des de l\u2019any 2018, l\u2019IDIBELL \u00e9s un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

Un treball de recerca liderat per neuroradi\u00f2legs i neur\u00f2legs de l\u2019IDIBELL, l\u2019Hospital Universitari de Bellvitge i l\u2019Institut de Diagn\u00f2stic per la Imatge ha identificat un nou biomarcador de resson\u00e0ncia magn\u00e8tica. Aquest biomarcador permetria detectar amb precisi\u00f3 focus d\u2019inflamaci\u00f3 cerebral cr\u00f2nica, associats a la forma progressiva de l\u2019esclerosi m\u00faltiple.<\/p>\n","protected":false},"author":8,"featured_media":24134,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[416,340,457],"tags":[],"class_list":["post-24133","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-malalties-neurologiques-i-neurogenetica","category-neurociencies","category-p-de-neurociencies"],"publishpress_future_action":{"enabled":false,"date":"2024-11-29 04:00:24","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/24133","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=24133"}],"version-history":[{"count":1,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/24133\/revisions"}],"predecessor-version":[{"id":24135,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/24133\/revisions\/24135"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/24134"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=24133"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=24133"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=24133"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}